CZ20012373A3 - Derivát azepinindolu, jeho pouľití a farmaceutický prostředek, který ho obsahuje - Google Patents

Derivát azepinindolu, jeho pouľití a farmaceutický prostředek, který ho obsahuje Download PDF

Info

Publication number: CZ20012373A3
Authority: CZ; Czechia
Prior art keywords: alkyl; carbon atoms; group; formula; compounds
Prior art date: 1999-09-28

Application number

CZ20012373A

Other languages

Czech (cs)

English (en)

Inventor

Wilfried Lubisch

Michael Kock

Thomas Höger

Sabine Schult

Roland Grandel

Reinhold MÜLLER

Original Assignee

Basf Aktiengesellschaft

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-09-28

Filing date

2000-09-15

Publication date

2002-05-15

1999-09-28 Priority claimed from DE19946289A external-priority patent/DE19946289A1/de

2000-08-09 Priority claimed from DE10039610A external-priority patent/DE10039610A1/de

2000-09-15 Application filed by Basf Aktiengesellschaft filed Critical Basf Aktiengesellschaft

2002-05-15 Publication of CZ20012373A3 publication Critical patent/CZ20012373A3/cs

Links

ISZIQZCZKOFSBT-UHFFFAOYSA-N pyrrolo[2,3-g][1]benzazepine Chemical class N1=CC=CC=C2C3=NC=CC3=CC=C21 ISZIQZCZKOFSBT-UHFFFAOYSA-N 0.000 title description 3
239000000825 pharmaceutical preparation Substances 0.000 title 1
150000001875 compounds Chemical class 0.000 claims abstract description 48
238000004519 manufacturing process Methods 0.000 claims abstract description 17
125000004432 carbon atom Chemical group C* 0.000 claims description 69
125000000217 alkyl group Chemical group 0.000 claims description 48
-1 trif1uormethyovou Chemical group 0.000 claims description 36
238000011282 treatment Methods 0.000 claims description 30
239000001257 hydrogen Substances 0.000 claims description 28
229910052739 hydrogen Inorganic materials 0.000 claims description 28
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 28
229910052799 carbon Inorganic materials 0.000 claims description 22
239000008194 pharmaceutical composition Substances 0.000 claims description 22
229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 claims description 18
229920006395 saturated elastomer Polymers 0.000 claims description 18
125000004434 sulfur atom Chemical group 0.000 claims description 17
125000002619 bicyclic group Chemical group 0.000 claims description 16
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 16
125000002950 monocyclic group Chemical group 0.000 claims description 16
125000004433 nitrogen atom Chemical group N* 0.000 claims description 14
125000006168 tricyclic group Chemical group 0.000 claims description 14
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 12
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 11
150000001721 carbon Chemical group 0.000 claims description 10
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 10
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 9
230000006378 damage Effects 0.000 claims description 9
125000004430 oxygen atom Chemical group O* 0.000 claims description 9
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 8
239000000460 chlorine Substances 0.000 claims description 8
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 8
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 7
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 7
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 7
125000005037 alkyl phenyl group Chemical group 0.000 claims description 7
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 7
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 7
229910052794 bromium Inorganic materials 0.000 claims description 7
229910052801 chlorine Inorganic materials 0.000 claims description 7
239000011737 fluorine Substances 0.000 claims description 7
229910052731 fluorine Inorganic materials 0.000 claims description 7
229910052757 nitrogen Inorganic materials 0.000 claims description 7
229910052760 oxygen Inorganic materials 0.000 claims description 7
239000001301 oxygen Substances 0.000 claims description 7
206010010904 Convulsion Diseases 0.000 claims description 6
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 6
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 6
125000004093 cyano group Chemical group *C#N 0.000 claims description 6
208000028867 ischemia Diseases 0.000 claims description 6
208000015122 neurodegenerative disease Diseases 0.000 claims description 6
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
229910052717 sulfur Inorganic materials 0.000 claims description 6
125000004429 atom Chemical group 0.000 claims description 5
125000001153 fluoro group Chemical group F* 0.000 claims description 5
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 5
238000011321 prophylaxis Methods 0.000 claims description 5
125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 4
FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical group C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 claims description 4
YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 4
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 4
UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical group C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 claims description 4
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 4
KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical group C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 4
SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical group N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims description 4
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 4
YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 4
125000003277 amino group Chemical group 0.000 claims description 4
210000001367 artery Anatomy 0.000 claims description 4
208000035475 disorder Diseases 0.000 claims description 4
239000003814 drug Substances 0.000 claims description 4
230000003961 neuronal insult Effects 0.000 claims description 4
239000011593 sulfur Substances 0.000 claims description 4
206010028980 Neoplasm Diseases 0.000 claims description 3
206010063897 Renal ischaemia Diseases 0.000 claims description 3
206010012601 diabetes mellitus Diseases 0.000 claims description 3
206010015037 epilepsy Diseases 0.000 claims description 3
208000026278 immune system disease Diseases 0.000 claims description 3
230000002401 inhibitory effect Effects 0.000 claims description 3
208000014674 injury Diseases 0.000 claims description 3
239000000546 pharmaceutical excipient Substances 0.000 claims description 3
206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
125000001424 substituent group Chemical group 0.000 claims description 3
238000002054 transplantation Methods 0.000 claims description 3
230000008733 trauma Effects 0.000 claims description 3
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 2
FTAHXMZRJCZXDL-UHFFFAOYSA-N 3-piperideine Chemical compound C1CC=CCN1 FTAHXMZRJCZXDL-UHFFFAOYSA-N 0.000 claims description 2
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 2
108010036949 Cyclosporine Proteins 0.000 claims description 2
206010019196 Head injury Diseases 0.000 claims description 2
208000023105 Huntington disease Diseases 0.000 claims description 2
206010061216 Infarction Diseases 0.000 claims description 2
206010061218 Inflammation Diseases 0.000 claims description 2
206010027476 Metastases Diseases 0.000 claims description 2
ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical group C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims description 2
WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical group C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims description 2
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical group C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 2
208000025747 Rheumatic disease Diseases 0.000 claims description 2
206010040070 Septic Shock Diseases 0.000 claims description 2
208000006011 Stroke Diseases 0.000 claims description 2
230000001154 acute effect Effects 0.000 claims description 2
206010000891 acute myocardial infarction Diseases 0.000 claims description 2
230000000740 bleeding effect Effects 0.000 claims description 2
230000003683 cardiac damage Effects 0.000 claims description 2
239000000969 carrier Substances 0.000 claims description 2
229960001265 ciclosporin Drugs 0.000 claims description 2
210000004351 coronary vessel Anatomy 0.000 claims description 2
125000004122 cyclic group Chemical group 0.000 claims description 2
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
230000009089 cytolysis Effects 0.000 claims description 2
208000028329 epileptic seizure Diseases 0.000 claims description 2
230000007574 infarction Effects 0.000 claims description 2
230000004054 inflammatory process Effects 0.000 claims description 2
125000000896 monocarboxylic acid group Chemical group 0.000 claims description 2
208000031225 myocardial ischemia Diseases 0.000 claims description 2
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Chemical group COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 2
238000002271 resection Methods 0.000 claims description 2
230000036303 septic shock Effects 0.000 claims description 2
208000011580 syndromic disease Diseases 0.000 claims description 2
229930192474 thiophene Chemical group 0.000 claims description 2
150000002431 hydrogen Chemical class 0.000 claims 9
KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical group C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims 2
MEUAVGJWGDPTLF-UHFFFAOYSA-N 4-(5-benzenesulfonylamino-1-methyl-1h-benzoimidazol-2-ylmethyl)-benzamidine Chemical compound N=1C2=CC(NS(=O)(=O)C=3C=CC=CC=3)=CC=C2N(C)C=1CC1=CC=C(C(N)=N)C=C1 MEUAVGJWGDPTLF-UHFFFAOYSA-N 0.000 claims 1
KKJUPNGICOCCDW-UHFFFAOYSA-N 7-N,N-Dimethylamino-1,2,3,4,5-pentathiocyclooctane Chemical compound CN(C)C1CSSSSSC1 KKJUPNGICOCCDW-UHFFFAOYSA-N 0.000 claims 1
208000024827 Alzheimer disease Diseases 0.000 claims 1
206010002329 Aneurysm Diseases 0.000 claims 1
208000018737 Parkinson disease Diseases 0.000 claims 1
PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Chemical group C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims 1
206010040047 Sepsis Diseases 0.000 claims 1
239000003513 alkali Substances 0.000 claims 1
ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 claims 1
230000000747 cardiac effect Effects 0.000 claims 1
229930182912 cyclosporin Natural products 0.000 claims 1
210000003709 heart valve Anatomy 0.000 claims 1
238000013160 medical therapy Methods 0.000 claims 1
230000002093 peripheral effect Effects 0.000 claims 1
230000000241 respiratory effect Effects 0.000 claims 1
230000000250 revascularization Effects 0.000 claims 1
238000001356 surgical procedure Methods 0.000 claims 1
238000002560 therapeutic procedure Methods 0.000 claims 1
239000000651 prodrug Substances 0.000 abstract description 4
229940002612 prodrug Drugs 0.000 abstract description 4
JBXRLVPILRXPNH-UHFFFAOYSA-N indol-6-one Chemical compound O=C1C=CC2=CC=NC2=C1 JBXRLVPILRXPNH-UHFFFAOYSA-N 0.000 description 28
102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 27
108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 27
239000000243 solution Substances 0.000 description 8
239000012661 PARP inhibitor Substances 0.000 description 6
229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 description 6
230000000694 effects Effects 0.000 description 6
239000011534 wash buffer Substances 0.000 description 5
102000004190 Enzymes Human genes 0.000 description 4
108090000790 Enzymes Proteins 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 4
239000004480 active ingredient Substances 0.000 description 4
201000010099 disease Diseases 0.000 description 4
239000003112 inhibitor Substances 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
108091003079 Bovine Serum Albumin Proteins 0.000 description 3
WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
239000002202 Polyethylene glycol Substances 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
239000002253 acid Substances 0.000 description 3
229940098773 bovine serum albumin Drugs 0.000 description 3
239000000872 buffer Substances 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
238000006911 enzymatic reaction Methods 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
238000000034 method Methods 0.000 description 3
239000000203 mixture Substances 0.000 description 3
210000000056 organ Anatomy 0.000 description 3
229920001223 polyethylene glycol Polymers 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
102220240796 rs553605556 Human genes 0.000 description 3
230000000699 topical effect Effects 0.000 description 3
238000005406 washing Methods 0.000 description 3
SQDFWBUESZGRBR-UHFFFAOYSA-N 1h-azepine;1h-indole Chemical class N1C=CC=CC=C1.C1=CC=C2NC=CC2=C1 SQDFWBUESZGRBR-UHFFFAOYSA-N 0.000 description 2
208000009304 Acute Kidney Injury Diseases 0.000 description 2
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
208000032843 Hemorrhage Diseases 0.000 description 2
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
208000033626 Renal failure acute Diseases 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
230000004913 activation Effects 0.000 description 2
239000004359 castor oil Substances 0.000 description 2
235000019438 castor oil Nutrition 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
235000019441 ethanol Nutrition 0.000 description 2
239000000499 gel Substances 0.000 description 2
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
238000001802 infusion Methods 0.000 description 2
208000010125 myocardial infarction Diseases 0.000 description 2
230000004770 neurodegeneration Effects 0.000 description 2
229960003966 nicotinamide Drugs 0.000 description 2
235000005152 nicotinamide Nutrition 0.000 description 2
239000011570 nicotinamide Substances 0.000 description 2
239000002674 ointment Substances 0.000 description 2
102000013415 peroxidase activity proteins Human genes 0.000 description 2
108040007629 peroxidase activity proteins Proteins 0.000 description 2
229940124531 pharmaceutical excipient Drugs 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000011535 reaction buffer Substances 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
239000007921 spray Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000000758 substrate Substances 0.000 description 2
125000004484 1-methylpiperidin-4-yl group Chemical group CN1CCC(CC1)* 0.000 description 1
FDSYTWVNUJTPMA-UHFFFAOYSA-N 2-[3,9-bis(carboxymethyl)-3,6,9,15-tetrazabicyclo[9.3.1]pentadeca-1(15),11,13-trien-6-yl]acetic acid Chemical compound C1N(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC2=CC=CC1=N2 FDSYTWVNUJTPMA-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
GSCPDZHWVNUUFI-UHFFFAOYSA-N 3-aminobenzamide Chemical compound NC(=O)C1=CC=CC(N)=C1 GSCPDZHWVNUUFI-UHFFFAOYSA-N 0.000 description 1
JODILMIKOIQVCF-UHFFFAOYSA-N 4-methyl-1-piperidin-1-ylpiperidine Chemical group C1CC(C)CCN1N1CCCCC1 JODILMIKOIQVCF-UHFFFAOYSA-N 0.000 description 1
XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 1
SRNWOUGRCWSEMX-TYASJMOZSA-N ADP-D-ribose Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H]1O)O)N1C=2N=CN=C(C=2N=C1)N)OP(O)(=O)OP(O)(=O)OC[C@H]1OC(O)[C@H](O)[C@@H]1O SRNWOUGRCWSEMX-TYASJMOZSA-N 0.000 description 1
XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
239000004322 Butylated hydroxytoluene Substances 0.000 description 1
NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
206010008342 Cervix carcinoma Diseases 0.000 description 1
230000005778 DNA damage Effects 0.000 description 1
231100000277 DNA damage Toxicity 0.000 description 1
206010012289 Dementia Diseases 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
239000004097 EU approved flavor enhancer Substances 0.000 description 1
108010033040 Histones Proteins 0.000 description 1
108010044467 Isoenzymes Proteins 0.000 description 1
229930194542 Keto Natural products 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
208000034486 Multi-organ failure Diseases 0.000 description 1
206010028347 Muscle twitching Diseases 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
102100023652 Poly [ADP-ribose] polymerase 2 Human genes 0.000 description 1
206010063837 Reperfusion injury Diseases 0.000 description 1
206010062657 Septic rash Diseases 0.000 description 1
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
229920002125 Sokalan® Polymers 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000013543 active substance Substances 0.000 description 1
201000011040 acute kidney failure Diseases 0.000 description 1
208000037892 acute myocardial injury Diseases 0.000 description 1
208000012998 acute renal failure Diseases 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
229940095259 butylated hydroxytoluene Drugs 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
230000005779 cell damage Effects 0.000 description 1
230000030833 cell death Effects 0.000 description 1
208000037887 cell injury Diseases 0.000 description 1
201000010881 cervical cancer Diseases 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
230000005796 circulatory shock Effects 0.000 description 1
239000012050 conventional carrier Substances 0.000 description 1
239000006071 cream Substances 0.000 description 1
GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
230000009429 distress Effects 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
238000001952 enzyme assay Methods 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
150000002191 fatty alcohols Chemical class 0.000 description 1
235000019264 food flavour enhancer Nutrition 0.000 description 1
208000005017 glioblastoma Diseases 0.000 description 1
229940100242 glycol stearate Drugs 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000006028 immune-suppresssive effect Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
239000000543 intermediate Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
230000000302 ischemic effect Effects 0.000 description 1
125000000468 ketone group Chemical group 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
239000008101 lactose Substances 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
229940057995 liquid paraffin Drugs 0.000 description 1
239000006210 lotion Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
230000002934 lysing effect Effects 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
230000007576 microinfarct Effects 0.000 description 1
208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
239000006072 paste Substances 0.000 description 1
230000004963 pathophysiological condition Effects 0.000 description 1
239000003208 petroleum Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
235000021317 phosphate Nutrition 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
239000004584 polyacrylic acid Substances 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
125000003373 pyrazinyl group Chemical group 0.000 description 1
230000035484 reaction time Effects 0.000 description 1
108091006091 regulatory enzymes Proteins 0.000 description 1
108010051412 reteplase Proteins 0.000 description 1
230000035939 shock Effects 0.000 description 1
235000002639 sodium chloride Nutrition 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
208000023516 stroke disease Diseases 0.000 description 1
150000003457 sulfones Chemical class 0.000 description 1
125000003375 sulfoxide group Chemical group 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
210000003478 temporal lobe Anatomy 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
235000010384 tocopherol Nutrition 0.000 description 1
229960001295 tocopherol Drugs 0.000 description 1
229930003799 tocopherol Natural products 0.000 description 1
239000011732 tocopherol Substances 0.000 description 1
210000002268 wool Anatomy 0.000 description 1
GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Pain & Pain Management (AREA)
Urology & Nephrology (AREA)
Rheumatology (AREA)
Psychology (AREA)
Emergency Medicine (AREA)
Hospice & Palliative Care (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Endocrinology (AREA)
Hematology (AREA)
Obesity (AREA)
Heart & Thoracic Surgery (AREA)
Psychiatry (AREA)
Pulmonology (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

CZ20012373A 1999-09-28 2000-09-15 Derivát azepinindolu, jeho pouľití a farmaceutický prostředek, který ho obsahuje CZ20012373A3 (cs)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE19946289A DE19946289A1 (de)	1999-09-28	1999-09-28	Benzodiazepin-Derivate, deren Herstellung und Anwendung
DE10039610A DE10039610A1 (de)	2000-08-09	2000-08-09	Azepinoindol-Derivate, deren Herstellung und Anwendung

Publications (1)

Publication Number	Publication Date
CZ20012373A3 true CZ20012373A3 (cs)	2002-05-15

Family

ID=26006691

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CZ20012373A CZ20012373A3 (cs)	1999-09-28	2000-09-15	Derivát azepinindolu, jeho pouľití a farmaceutický prostředek, který ho obsahuje

Country Status (17)

Country	Link
EP (1)	EP1183259A2 (de)
JP (1)	JP2003510328A (de)
KR (1)	KR20010087401A (de)
CN (1)	CN1374961A (de)
AU (1)	AU1271201A (de)
BG (1)	BG105650A (de)
BR (1)	BR0007174A (de)
CA (1)	CA2352194A1 (de)
CZ (1)	CZ20012373A3 (de)
HK (1)	HK1048999A1 (de)
HU (1)	HUP0104917A3 (de)
IL (1)	IL143349A0 (de)
NO (1)	NO20012567L (de)
PL (1)	PL347885A1 (de)
SK (1)	SK8842001A3 (de)
TR (1)	TR200101499T1 (de)
WO (1)	WO2001023390A2 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL210415B1 (pl)	1999-01-11	2012-01-31	Agouron Pharma	Pochodne indolu, środek farmaceutyczny i zastosowanie pochodnych indolu
US7151102B2 (en)	2000-10-30	2006-12-19	Kudos Pharmaceuticals Limited	Phthalazinone derivatives
ATE478664T1 (de)	2000-12-01	2010-09-15	Eisai Inc	Azaphenanthridone-derivate und deren verwendung als parp-inhibitoren
US7026311B2 (en)	2002-01-10	2006-04-11	Abbott Gmbh & Co., Kg	Dibenzodiazepine derivatives, their preparation and use
EP1501822B1 (de)	2002-04-30	2010-12-15	Kudos Pharmaceuticals Limited	Phthalazinonderivate
EP1527183B1 (de)	2002-07-26	2008-08-20	BASF Plant Science GmbH	Neue selektionsverfahren
US7449464B2 (en)	2003-03-12	2008-11-11	Kudos Pharmaceuticals Limited	Phthalazinone derivatives
GB0305681D0 (en)	2003-03-12	2003-04-16	Kudos Pharm Ltd	Phthalazinone derivatives
WO2005028467A1 (en)	2003-09-15	2005-03-31	Anadys Pharmaceuticals, Inc.	Antibacterial 3,5-diaminopiperidine-substitute aromatic and heteroaromatic compounds
CA2547077C (en)	2003-12-01	2015-11-03	Kudos Pharmaceuticals Limited	Dna damage repair inhibitors for treatment of cancer
US7772271B2 (en)	2004-07-14	2010-08-10	Ptc Therapeutics, Inc.	Methods for treating hepatitis C
US7868037B2 (en)	2004-07-14	2011-01-11	Ptc Therapeutics, Inc.	Methods for treating hepatitis C
US7781478B2 (en)	2004-07-14	2010-08-24	Ptc Therapeutics, Inc.	Methods for treating hepatitis C
EA200700243A1 (ru)	2004-07-14	2007-08-31	ПиТиСи ТЕРАПЬЮТИКС, ИНК.	Способы лечения гепатита с
CA2578636A1 (en)	2004-07-22	2006-02-23	Ptc Therapeutics, Inc.	Thienopyridines for treating hepatitis c
GB0419072D0 (en)	2004-08-26	2004-09-29	Kudos Pharm Ltd	Phthalazinone derivatives
EP2166099B1 (de)	2005-03-08	2012-12-19	BASF Plant Science GmbH	Expressionsverstärkende Intronsequenzen
WO2006101937A1 (en)	2005-03-18	2006-09-28	Janssen Pharmaceutica N.V.	Acylhydrazones as kinase modulators
GB0521373D0 (en)	2005-10-20	2005-11-30	Kudos Pharm Ltd	Pthalazinone derivatives
TWI404716B (zh)	2006-10-17	2013-08-11	Kudos Pharm Ltd	酞嗪酮（ｐｈｔｈａｌａｚｉｎｏｎｅ）衍生物
EP2188278A1 (de)	2007-09-14	2010-05-26	AstraZeneca AB	Phthalazinonderivate
UY31603A1 (es)	2008-01-23	2009-08-31		Derivados de ftalazinona
GB0804755D0 (en) *	2008-03-14	2008-04-16	Angeletti P Ist Richerche Bio	Therapeutic compounds
CA2737400C (en)	2008-10-07	2016-11-22	Astrazeneca Uk Limited	Pharmaceutical formulation 514
WO2011058367A2 (en)	2009-11-13	2011-05-19	Astrazeneca Ab	Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor
CN102762726A (zh)	2009-11-27	2012-10-31	巴斯夫植物科学有限公司	嵌合内切核酸酶及其用途
AU2010325549B2 (en)	2009-11-27	2017-04-20	Basf Plant Science Company Gmbh	Optimized endonucleases and uses thereof
US10316304B2 (en)	2009-11-27	2019-06-11	Basf Plant Science Company Gmbh	Chimeric endonucleases and uses thereof
EP2575815A4 (de)	2010-06-04	2013-12-25	Albany Molecular Res Inc	Glycin-transporter-1-hemmer, verfahren zu ihrer herstellung und ihre verwendung
JP6457696B2 (ja)	2015-07-23	2019-01-23	アンスティテュ・キュリＩｎｓｔｉｔｕｔＣｕｒｉｅ	癌を処置するためのＤｂａｉｔ分子とＰＡＲＰインヒビターとの組合せの使用
GB201519573D0 (en)	2015-11-05	2015-12-23	King S College London	Combination
WO2018162439A1 (en)	2017-03-08	2018-09-13	Onxeo	New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
AU2018260094A1 (en)	2017-04-28	2019-11-07	Akribes Biomedical Gmbh	A PARP inhibitor in combination with a glucocorticoid and/or ascorbic acid and/or a protein growth factor for the treatment of impaired wound healing
CN110997068B (zh) *	2017-05-24	2022-12-06	宾夕法尼亚大学董事会	用于成像和放射疗法的经放射标记的荧光parp抑制剂
WO2019175132A1 (en)	2018-03-13	2019-09-19	Onxeo	A dbait molecule against acquired resistance in the treatment of cancer
US11034669B2 (en)	2018-11-30	2021-06-15	Nuvation Bio Inc.	Pyrrole and pyrazole compounds and methods of use thereof
CA3128435A1 (en) *	2019-02-02	2020-08-06	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Indolo heptamyl oxime analogue as parp inhibitor
WO2021018298A1 (zh) *	2019-08-01	2021-02-04	南京明德新药研发有限公司	作为parp抑制剂吲哚并七元酰肟化合物
GB201913030D0 (en)	2019-09-10	2019-10-23	Francis Crick Institute Ltd	Treatment of hr deficient cancer
WO2021148581A1 (en)	2020-01-22	2021-07-29	Onxeo	Novel dbait molecule and its use
CN115698019B (zh) *	2020-07-31	2024-12-06	正大天晴药业集团股份有限公司	用作parp抑制剂的吲哚并七元酰肟类似物的结晶及其制备方法
WO2024261243A1 (en)	2023-06-21	2024-12-26	Hemispherian As	Combination comprising a deoxycytidine derivative and a parp inhibitor for use in a method of treating hr proficient cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1999011644A1 (en) *	1997-09-03	1999-03-11	Guilford Pharmaceuticals Inc.	Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity
PL210415B1 (pl) *	1999-01-11	2012-01-31	Agouron Pharma	Pochodne indolu, środek farmaceutyczny i zastosowanie pochodnych indolu
ECSP003637A (es) *	1999-08-31	2002-03-25	Agouron Pharma	Inhibidores triciclicos de poli (adp-ribosa) polimerasas

2000
- 2000-09-15 WO PCT/EP2000/009024 patent/WO2001023390A2/de not_active Ceased
- 2000-09-15 KR KR1020017006614A patent/KR20010087401A/ko not_active Ceased
- 2000-09-15 HK HK03101179.8A patent/HK1048999A1/zh unknown
- 2000-09-15 HU HU0104917A patent/HUP0104917A3/hu unknown
- 2000-09-15 CN CN00802408A patent/CN1374961A/zh active Pending
- 2000-09-15 EP EP00974379A patent/EP1183259A2/de not_active Withdrawn
- 2000-09-15 IL IL14334900A patent/IL143349A0/xx unknown
- 2000-09-15 AU AU12712/01A patent/AU1271201A/en not_active Abandoned
- 2000-09-15 BR BR0007174-9A patent/BR0007174A/pt not_active IP Right Cessation
- 2000-09-15 JP JP2001526542A patent/JP2003510328A/ja active Pending
- 2000-09-15 CA CA002352194A patent/CA2352194A1/en not_active Abandoned
- 2000-09-15 CZ CZ20012373A patent/CZ20012373A3/cs unknown
- 2000-09-15 TR TR2001/01499T patent/TR200101499T1/xx unknown
- 2000-09-15 SK SK884-2001A patent/SK8842001A3/sk unknown
- 2000-09-15 PL PL00347885A patent/PL347885A1/xx not_active Application Discontinuation
2001
- 2001-05-25 NO NO20012567A patent/NO20012567L/no not_active Application Discontinuation
- 2001-06-26 BG BG105650A patent/BG105650A/xx unknown

Also Published As

Publication number	Publication date
WO2001023390A3 (de)	2001-12-27
AU1271201A (en)	2001-04-30
EP1183259A2 (de)	2002-03-06
NO20012567L (no)	2001-06-25
HK1048999A1 (zh)	2003-04-25
NO20012567D0 (no)	2001-05-25
PL347885A1 (en)	2002-04-22
SK8842001A3 (en)	2002-01-07
HUP0104917A2 (hu)	2002-04-29
BG105650A (en)	2002-02-28
BR0007174A (pt)	2001-09-04
CA2352194A1 (en)	2001-04-05
CN1374961A (zh)	2002-10-16
JP2003510328A (ja)	2003-03-18
HUP0104917A3 (en)	2002-12-28
IL143349A0 (en)	2002-04-21
KR20010087401A (ko)	2001-09-15
TR200101499T1 (tr)	2002-09-23
WO2001023390A2 (de)	2001-04-05

Publication	Publication Date	Title
CZ20012373A3 (cs)	2002-05-15	Derivát azepinindolu, jeho pouľití a farmaceutický prostředek, který ho obsahuje
US7087637B2 (en)	2006-08-08	Substituted indoles which are PARP inhibitors
US8318720B2 (en)	2012-11-27	Acrylamide derivatives as Fab I inhibitors
US9029392B2 (en)	2015-05-12	Quinoline derivatives as kinase inhibitors
JP2020189855A (ja)	2020-11-26	ピラゾール−アミド化合物およびその医薬用途
SK286676B6 (sk)	2009-03-05	Použitie ftalazínových derivátov
PL196367B1 (pl)	2007-12-31	Podstawione benzimidazole, ich zastosowanie jako inhibitorów PARP oraz środek leczniczy
CZ20011724A3 (cs)	2001-08-15	Použití derivátu 2-fenylbenzimidazolu a 2-fenylindolu pro výrobu drog
HUP0203225A2 (hu)	2003-01-28	Benzodiazepinszármazékok, előállításuk és alkalmazásuk
US20080261975A1 (en)	2008-10-23	Tec Kinase Inhibitors
CZ20013775A3 (cs)	2002-10-16	Derivát benzimidazolu substituovaný cykloalkylovou skupinou, způsob jeho přípravy a jeho pouľití
JP2008156370A (ja)	2008-07-10	Ｊａｋおよび他のプロテインキナーゼの阻害剤として有用なアザインドール
US20060183908A1 (en)	2006-08-17	Heterocyclic compounds, methods of making them and their use in therapy
AU2002211827B2 (en)	2006-12-14	Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same
CA2388729A1 (en)	2001-05-17	Imidazopyridine derivatives as phosphodiesterase vii inhibitors
CA2436770A1 (en)	2002-08-08	Methods of treating inflammatory and immune diseases using inhibitors of ikb kinase (ikk)
US7026311B2 (en)	2006-04-11	Dibenzodiazepine derivatives, their preparation and use
KR101048377B1 (ko)	2011-07-11	2,4-비스(트리플루오로에톡시)피리딘 화합물 및 이를함유하는 의약.
MXPA01005199A (en)	2002-06-05	Azepinoindole derivatives, the production and use thereof
TWI287015B (en)	2007-09-21	N-6 substituted 7-deazapurine compounds as adenosine receptor antagonists